Brief: Vicore Pharma Gets Regulatory Approval To Start Phase II Clinical Trial With VP01
05/05/2020 06:56
May 5 (Reuters) - Vicore Pharma Holding AB VICOR.ST :
* VICORE PHARMA RECEIVES REGULATORY APPROVAL TO START PHASE
II
CLINICAL TRIAL WITH VP01 (C21) IN PATIENTS WITH IPF
* ANNOUNCES APPROVAL BY UK REGULATORY AGENCY (MHRA(1)) OF
CLINICAL
TRIAL APPLICATION (CTA) FOR A PHASE II STUDY WITH ITS
PROPRIETARY COMPOUND VP01 (C21) IN PATIENTS WITH IPF (IDIOPATHIC
PULMONARY FIBROSIS)
* DEPENDING ON COVID-19 SITUATION, VICORE PHARMA ANTICIPATES
THAT
PATIENT RECRUITMENT MAY START DURING Q3 OF 2020
Source text for Eikon: ID:nWkr80MZCB
Further company coverage: VICOR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2